Table 11.
Adverse events related to the intervention.
| Ref | Type of growth factor | Drug-related main adverse effects | ||||
|---|---|---|---|---|---|---|
| Pain | Erythema and edema | Cellulitis | Infection | Others | ||
| [8–14, 48] | PDGF | N | N | N | N | |
| [21–24] | FGF | N | N | N | N | |
| [16–20] | EGF | N | N | N | N | Dizziness, shivering, and chills appeared more frequently in the EGF-treated groups, apparently dose-dependent |
| [25–28] | G-CSF | N | N | N | N | Worsened liver function, skin efflorescence |
| [29] | VEGF | N | N | N | N | |
| [30] | Erythropoietin, epoetin beta | N | N | N | N | |
| [31] | Talactoferrin | N | N | N | N | |
| [32] | Chrysalin® | N | N | N | N | |
| [33] | TGF-β | N | N | N | N | |
PDGF: platelet-derived growth factor; G-CSF: granulocyte colony-stimulating factor; VEGF: vascular endothelial growth factor; TGF-β: transforming growth factor β; N: no drug-related side effect.